Versha Banerji
0000-0002-7415-8818
Publication & Citation Trends
Most Cited Works
Publications
159 total
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
Cited by 50
OpenAlex
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia PDF
Cited by 194
OpenAlex
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial PDF
Cited by 592
OpenAlex
ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Cited by 61
OpenAlex
Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival
Cited by 44
OpenAlex
Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration PDF
Cited by 45
OpenAlex
Research Topics
Chronic Lymphocytic Leukemia Research
(110)
Lymphoma Diagnosis and Treatment
(60)
Immunodeficiency and Autoimmune Disorders
(26)
Biochemical and Molecular Research
(22)
Acute Lymphoblastic Leukemia research
(18)
Frequent Co-Authors
Affiliations
Broad Institute
Manitoba Health
Boston Children's Hospital
Harvard University
University of Connecticut